---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000136"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:02:41.044651+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MaxCyte reports prelim Q4 total revenue $15.5-15.7M, core down YoY; FY total revenue $41.1-41.3M

## Summary
- Q4 2023 total revenue expected $15.5-15.7M (Q4 2022: $12.4M); core revenue $7.0-7.2M (down from $10.6M) and SPL revenue ~$8.5M (up from $1.9M).
- FY 2023 total revenue expected $41.1-41.3M (FY 2022: $44.3M); core revenue $29.6-29.8M (down from $39.6M), SPL ~$11.4M (up from $4.6M).
- Cash, equivalents and investments ~$210M as of Dec 31, 2023.
- Management cited Vertex CASGEVY FDA approval as milestone validating platform; core revenue decline reflects cell therapy industry headwinds.
- Results are preliminary, unaudited; audited statements expected in March 2024.

## SEC filing metadata
- accession: 0001558370-24-000136
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/mxct-20240108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000136
- JSON: https://secwatch.observer/filing/0001558370-24-000136.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000136.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $15.5 million and $15.7 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: between $15.5 million and $15.7 million
  - Result: preliminary results
  source text: Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm
- Earnings Releases
  MAXCYTE, INC. reported the fiscal year ended December 31, 2023 results: revenue between $41.1 and $41.3 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: between $41.1 and $41.3 million
  - Result: preliminary results
  source text: Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837024000136/0001558370-24-000136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.